Detalhe da pesquisa
1.
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Cancer
; 130(9): 1663-1672, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127583
2.
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Br J Haematol
; 204(5): 1944-1952, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448009
3.
A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
Blood
; 139(9): 1289-1301, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521108
4.
Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts.
Am J Hematol
; 99(2): 245-253, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38100199
5.
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study.
Am J Hematol
; 99(4): 562-569, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38314663
6.
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.
Br J Haematol
; 202(4): 866-873, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37376789
7.
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.
Am J Hematol
; 98(10): 1571-1578, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37461327
8.
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
Blood
; 135(6): 449-452, 2020 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826244
9.
Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome.
Cancer
; 127(10): 1598-1605, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33471943
10.
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Cancer
; 127(1): 82-92, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966625
11.
Chimeric antigen receptor T-cell therapy toxicities.
Br J Clin Pharmacol
; 87(6): 2414-2424, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32463929
12.
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia.
Acta Haematol
; 144(1): 74-81, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32604096
13.
Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 26(1): 197-203, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31518645
14.
Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 26(6): 1077-1083, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31786242
15.
Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Biol Blood Marrow Transplant
; 26(4): 665-671, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31881283
16.
Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Cancer
; 126(10): 2183-2192, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32101640
17.
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
Biol Blood Marrow Transplant
; 25(7): 1347-1354, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30826465
18.
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Biol Blood Marrow Transplant
; 25(5): 1039-1044, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30639822
19.
Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.
Biol Blood Marrow Transplant
; 25(2): 335-342, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30243581
20.
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.
Biol Blood Marrow Transplant
; 25(7): 1340-1346, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30763728